Phase III Study of Avastin Plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary Endpoint

Phase III Study of Avastin Plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary Endpoint
SOUTH SAN FRANCISCO, Calif.—-Genentech, Inc., a wholly owned member of the Roche Group , today announced that a Phase III study did not meet its primary endpoint of showing Avastin® plus Xeloda® or 5-FU and cisplatin [...]